• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.

作者信息

Söhngen W, Mickelson J K, Simpson P J, Lucchesi B R

机构信息

Department of Pharmacology, University of Michigan Medical School, Ann Arbor.

出版信息

Thromb Res. 1988 Jul 1;51(1):63-74. doi: 10.1016/0049-3848(88)90283-6.

DOI:10.1016/0049-3848(88)90283-6
PMID:3137691
Abstract

The thrombolytic efficacy of recombinant single-chain urokinase-type plasminogen activator (rscu-PA) was studied in an open-chest canine model of coronary artery thrombosis. Dogs (n = 16) were anesthetized, a left thoracotomy performed, and a two cm segment of the left circumflex coronary artery was isolated and instrumented with an electromagnetic flow probe, an intracoronary stimulation electrode, and an adjustable mechanical occluder. Anodal direct current (100 microA) was applied to the stimulation electrode until thrombosis occurred (n = 14). After 30 min of thrombotic occlusion, rscu-PA was administered intravenously. Dogs were sacrificed either 6 h after thrombolysis or 6.5 h after initiation of rscu-PA when thrombolysis did not occur. In group A (30-50 micrograms/kg bolus rscu-PA + 20-40 micrograms/kg/min infusion rscu-PA for 30 min, n = 5) thrombolysis occurred in one case (20%) and this artery reoccluded. In group B (250 micrograms/kg bolus rscu-PA + 25 micrograms/kg/min infusion rscu-PA for 30 min, n = 6) all reperfused and only one reoccluded (16.6%). In group C (200 micrograms/kg bolus rscu-PA + 100 micrograms/kg/min rscu-PA infusion for 30 min, n = 2) both reperfused and neither reoccluded. Infarct size, determined as a percentage of left ventricle, was smaller when thrombolysis was followed by persistent reperfusion (n = 7), than when reperfusion did not occur (n = 4): 16.9 +/- 3.7% vs 31.3 +/- 2.2%, respectively (mean +/- SEM, p less than 0.02). If thrombolysis was followed by reocclusion, infarct size was 27.0 +/- 10.0%. In this study thrombolysis occurred when changes in prothrombin time, partial thromboplastin time, fibrinogen and fibrin split products were suggestive of systemic finbrinogenolysis. In conclusion, effective thrombolysis with rscu-PA appears to limit infarct size and to be accompanied by evidence of systemic fibrinolysis.

摘要

相似文献

1
Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Thromb Res. 1988 Jul 1;51(1):63-74. doi: 10.1016/0049-3848(88)90283-6.
2
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.重组人组织型纤溶酶原激活剂与人类单链尿激酶型纤溶酶原激活剂的协同组合。对严重狭窄犬冠状动脉血栓形成模型中溶栓及再闭塞的影响。
Circulation. 1989 Feb;79(2):393-9. doi: 10.1161/01.cir.79.2.393.
3
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
J Cardiovasc Pharmacol. 1987 Jan;9(1):91-3.
4
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.重组单链尿激酶型纤溶酶原激活剂(沙芦普酶)静脉推注或持续输注用于溶栓的比较。犬冠状动脉和股静脉联合血栓形成模型。
Blood. 1990 Oct 15;76(8):1558-63.
5
Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Circulation. 1984 Oct;70(4):700-7. doi: 10.1161/01.cir.70.4.700.
6
Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.重组组织型纤溶酶原激活剂单次大剂量给药:对血栓闭塞/再灌注犬模型中梗死相关血管通畅、微血管灌注和微血管再闭塞的影响
Cardiovasc Res. 1991 Mar;25(3):184-91. doi: 10.1093/cvr/25.3.184.
7
Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
Arzneimittelforschung. 1988 Jan;38(1):138-42.
8
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.在犬动静脉联合血栓形成模型中组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(u-PA)和K1K2Pu(一种t-PA/u-PA嵌合体)的溶栓特性比较
J Am Coll Cardiol. 1992 May;19(6):1350-9. doi: 10.1016/0735-1097(92)90344-m.
9
Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.在犬冠状动脉血栓形成模型中,将依前列醇类似物他前列烯与重组单链尿激酶型纤溶酶原激活剂联合使用实现额外的心肌挽救。
Arzneimittelforschung. 1989 Apr;39(4):534-8.
10
Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.7E3给药时间对rt-PA诱导再灌注的影响:基于血栓闭塞-再灌注犬模型的研究
Eur J Pharmacol. 1999 Jun 25;374(3):399-410. doi: 10.1016/s0014-2999(99)00324-6.

引用本文的文献

1
Saruplase in Myocardial Infarction.沙芦普酶治疗心肌梗死
J Thromb Thrombolysis. 1995;2(3):195-204. doi: 10.1007/BF01062710.
2
A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.沙芦普酶与尿激酶治疗急性心肌梗死疗效及安全性的双盲多中心比较:SUTAMI研究组报告
J Thromb Thrombolysis. 1995;2(2):117-124. doi: 10.1007/BF01064379.